Revvity, Inc. (NYSE:RVTY) Insider Tajinder S. Vohra Sells 2,154 Shares

Revvity, Inc. (NYSE:RVTY) insider Tajinder S. Vohra sold 2,154 shares of Revvity stock in a transaction on Wednesday, October 9th. The shares were sold at an average price of $121.73, for a total value of $262,206.42. Following the completion of the transaction, the insider now owns 19,652 shares in the company, valued at $2,392,237.96. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Revvity Stock Performance

Shares of RVTY opened at $120.23 on Friday. The stock has a 50-day moving average of $121.49 and a two-hundred day moving average of $112.21. Revvity, Inc. has a one year low of $79.50 and a one year high of $128.15. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.98 and a current ratio of 2.27. The stock has a market cap of $14.83 billion, a P/E ratio of 87.12, a P/E/G ratio of 3.35 and a beta of 1.05.

Revvity (NYSE:RVTY) last issued its quarterly earnings results on Monday, July 29th. The company reported $1.22 EPS for the quarter, topping analysts’ consensus estimates of $1.12 by $0.10. Revvity had a return on equity of 7.34% and a net margin of 6.26%. The company had revenue of $691.70 million during the quarter, compared to analysts’ expectations of $690.33 million. During the same quarter in the previous year, the firm posted $1.21 EPS. The firm’s revenue was down 2.5% compared to the same quarter last year. As a group, research analysts predict that Revvity, Inc. will post 4.75 EPS for the current year.

Revvity Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, November 8th. Stockholders of record on Friday, October 18th will be issued a $0.07 dividend. The ex-dividend date is Friday, October 18th. This represents a $0.28 annualized dividend and a dividend yield of 0.23%. Revvity’s dividend payout ratio (DPR) is presently 20.29%.

Wall Street Analysts Forecast Growth

RVTY has been the topic of a number of analyst reports. Citigroup lifted their price target on Revvity from $135.00 to $145.00 and gave the company a “buy” rating in a report on Tuesday, July 30th. Leerink Partnrs upgraded Revvity to a “strong-buy” rating in a report on Monday, July 8th. JPMorgan Chase & Co. lifted their price target on Revvity from $105.00 to $120.00 and gave the company a “neutral” rating in a report on Tuesday, July 30th. Wells Fargo & Company started coverage on Revvity in a research note on Tuesday, August 27th. They set an “equal weight” rating and a $130.00 target price on the stock. Finally, Leerink Partners started coverage on Revvity in a research note on Monday, July 8th. They set an “outperform” rating and a $125.00 target price on the stock. Eight research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Revvity presently has a consensus rating of “Moderate Buy” and an average target price of $125.53.

Hedge Funds Weigh In On Revvity

Several institutional investors and hedge funds have recently modified their holdings of RVTY. Prudential PLC acquired a new position in shares of Revvity in the 4th quarter valued at about $578,000. Connectus Wealth LLC acquired a new position in shares of Revvity in the 4th quarter valued at about $566,000. First Light Asset Management LLC acquired a new position in shares of Revvity in the 4th quarter valued at about $243,000. Guardian Wealth Management Inc. acquired a new position in shares of Revvity in the 4th quarter valued at about $1,315,000. Finally, Secured Retirement Advisors LLC acquired a new position in shares of Revvity in the 4th quarter valued at about $794,000. Institutional investors and hedge funds own 86.65% of the company’s stock.

About Revvity

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.